28
Participants
Start Date
January 24, 2023
Primary Completion Date
August 31, 2025
Study Completion Date
August 31, 2027
CNTY-101
CNTY-101 cells for intravenous (IV) infusion
IL-2
IL-2 subcutaneous (SQ) injection
Lymphodepleting Chemotherapy
LDC as prespecified in the protocol.
Medstar Georgetown University Hospital, Washington D.C.
University of Maryland Medical Center, Baltimore
Virginia Oncology Associates, Norfolk
Levine Cancer Institute, Charlotte
Vanderbilt University Medical Center, Nashville
University of Kentucky - Markey Cancer Center, Lexington
University of Cincinnati Medical Center, Cincinnati
Oncology Hematology Care, Inc-Kenwood, Cincinnati
Henry Ford Hospital, Detroit
Corewell Health, Grand Rapids
UT Southwestern, Dallas
Houston Methodist Research Institute, Houston
Banner MD Anderson Cancer Center, Gilbert
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles
University of California San Diego, Moores Cancer Center, San Diego
Swedish Cancer Institute, Seattle
Lead Sponsor
Century Therapeutics, Inc.
INDUSTRY